Viridian Therapeutics, Inc.
VRDN
$23.01
-$0.17-0.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.47% | -16.95% | -26.91% | -17.46% | -50.87% |
| Total Depreciation and Amortization | -3.11% | -9.38% | -14.81% | -88.08% | -15.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 90.42% | 50.74% | 55.39% | -23.37% | -43.56% |
| Change in Net Operating Assets | -140.53% | 2,110.56% | 139.96% | -492.15% | -29.40% |
| Cash from Operations | -7.86% | -8.45% | -18.97% | -65.48% | -83.68% |
| Capital Expenditure | -217.01% | 27.64% | 3.13% | 17.08% | 3.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,372.21% | -498.14% | 83.75% | 171.44% | 114.21% |
| Cash from Investing | -1,402.36% | -517.57% | 83.57% | 171.23% | 113.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 80.29% | 29.22% | -20.16% | -89.58% | -12.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -67.19% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 191.85% | 285.35% | 214.62% | 95.39% | 26.87% |
| Cash from Financing | 157.55% | 46.23% | -6.77% | -90.93% | -25.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 393.55% | 144.69% | 3,588.65% | -134.57% | -53.09% |